The laboratory information management system (LIMS) landscape in 2024 is a dynamic one, driven by accelerating advancements in technology and evolving industry needs. This article shares the four key trends.
- What Proposed Plasmid DNA Standards Say For GMP/Non-GMP Production
- Drugging The Undruggable: Strategies And Future Directions
- 8 Key Takeaways Of The Proposed FDA Modernization Act 3.0
- Shocking! Biotech Facilities Don't Maintain Themselves
- The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz
- Exploring Biolistic Particle Delivery Systems
- Comparability Considerations For mRNA Product Development
- FDA’s Updated Guidance On Human Genome Editing: New Implications & Remaining Questions
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Improve Your Molecular Cloning Process With Synthetic Biology Automation
Explore the promising field of synthetic biology, the hurdles manufacturers face with it's workflow, and how automation can help accelerating throughput and walkaway time.
-
Nucleases - Are They A Problem For NAB Nanosep® Centrifugal Devices?
We examine whether the sample tubes and collection tubes of the NAB Nanosep centrifugal devices contain detectable amounts of DNase or RNase.
-
Eliminating USP <88> In Vivo Animal Bioreactivity Testing For Polymer Characterization
There has been growing awareness about the environmental and ethical implications of plastics used in bioprocessing. The time for a shift to well-studied, proven in vitro cytotoxicity testing is now.
-
Optimizing AAV Purification for High Recovery
How can you improve purification methods for your AAVs and enhance the efficacy and safety of your gene therapy treatments?
-
Flow Cytometry Analysis Of Chemokine Receptors Expressed On Human NK Cells
Learn how the knowledge generated by a deep and thorough analysis of chemokine receptors on natural killer (NK) cells can be helpful to scientists studying certain cancers and diseases.
-
AAV Thermostability Assessment With Micro-Flow Imaging
This study demonstrates a micro-flow imaging system's ability to evaluate AAV9 particle purity and stability when subjected to heat stress at two different temperatures: 37°C and 75°C.
-
How Community Oncologists View CAR T-Cell Therapy Possibilities And Challenges
Learn how a partner with innovative solutions aimed at overcoming the barriers that limit the real-world impact of CAR T-cell therapy can make these advanced therapies more accessible and affordable.
-
Advanced Bioscience Laboratories Inc. (ABL) Scaled Up Lentiviral Production
ABL scaled up the production of lentivirus from adherent cells in a well-established and proven bioreactor system that's accepted by regulatory agencies, thus reducing risk and time to market.
-
Chromatographic Separation Of Full And Empty AAV8 Capsids
Here, we demonstrate a rapid method for the separation of empty and full AAV8 particles by linear gradient elution on CIMmultus® QA monoliths with 80% recovery.
-
Managing Cash Flow And Financial Risk For Cell And Gene Therapies
Pharmaceutical companies that are able to mitigate financial risk for CGT providers and ease cash flow burdens will stand out as preferred partners in an increasingly competitive industry.
NEWSLETTER ARCHIVE
- 03.18.24 -- Bringing Therapies To Patients With Speed And Confidence
- 03.18.24 -- Reducing Batch-To-Batch Variation In Cell Therapy Manufacturing
- 03.14.24 -- Explore Revolutionary Research Shaping Medicine
- 03.14.24 -- mRNA: Challenges & Opportunities For Scale-Out, Optimization
- 03.13.24 -- Regulatory & GMP Manufacturing Insights Into mRNA-LNP Drug Products
- Rare Disease Day 2024
- Video Clips From Cell & Gene Live: 2024 Regulatory Outlook With FDA's Dr. Peter Marks And Dr. Nicole Verdun
- Inside Cell & Gene Live “How To Reduce Batch-To-Batch Variation In Cell Therapy Manufacturing”
- Mass General Cancer Center’s Dr. Genevieve Boland on Amtagvi Approval
- Inside Cell & Gene Live “2024 Regulatory Outlook With FDA’s Dr. Peter Marks And Dr. Nicole Verdun”
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections